Showing 1 - 3 results of 3 for search 'Hasumati Rahalkar', query time: 0.03s Refine Results
  1. 1
    Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines

    Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines by Hasumati Rahalkar, Hasumati Rahalkar, Hacer Coskun Cetintas, Sam Salek

    Published 2018-09-01
    Get full text
    Article
  2. 2
    Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices

    Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices by Hasumati Rahalkar, Hasumati Rahalkar, Alan Sheppard, Sam Salek, Sam Salek

    Published 2021-08-01
    Get full text
    Article
  3. 3
    Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities

    Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities by Hasumati Rahalkar, Hasumati Rahalkar, Alan Sheppard, Gustavo Mendes Lima Santos, Chitralekha Dasgupta, Sonia Mayra Perez-Tapia, Carlos A. Lopez-Morales, Sam Salek, Sam Salek

    Published 2021-09-01
    Get full text
    Article

Search Tools: